Is it Uveitis? Identifying and Managing Challenging Cases in Chronic Postsurgical Inflammation (Online CME Monograph)
Activity Description and Purpose
Posterior segment ocular inflammation (uveitis) is a common complication of ocular surgery that can lead to cystoid macular edema and poor visual outcomes. Management of posterior segment inflammation often consists of repeated treatments of topical, systemic, or intravitreal corticosteroids. These approaches can have drawbacks of duration, safety, and burden. Novel treatment options are now available to expand the therapeutic armamentarium for the management of chronic postoperative inflammation. This educational activity aims to educate retina specialists and other ophthalmologists on postsurgical uveitis, including current evidence-based treatments and strategies for incorporating best practices into patient care. The desired results of this activity are for retina specialists and other ophthalmologists to recognize postoperative chronic posterior segment inflammation (uveitis) as part of the spectrum of uveitides and to select treatments that balance safety and efficacy.
This educational activity is intended for retina specialists and other ophthalmologists.
After completing this activity, participants will be better able to:
- Describe evidence-based treatments for posterior segment inflammation (uveitis) and cystoid macular edema following ocular surgery
- Design treatment plans for posterior segment inflammation (uveitis) and cystoid macular edema that balance safety and efficacy following ocular surgery
|David Eichenbaum, MD (Chair)|
Collaborative Associate Professor of Ophthalmology
Morsani College of Medicine
University of South Florida
Partner and Director of Research
Retina Vitreous Associates of Florida
|Dilraj S. Grewal, MD|
Associate Professor of Ophthalmology
Duke Eye Center
Durham, North Carolina
|Daniel F. Kiernan, MD, FACS|
The Eye Associates
Clinical Adjunct Faculty
Department of Ophthalmology
Sarasota Memorial Hospital
|Aleksandra V. Rachitskaya, MD|
Department of Ophthalmology
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
Cole Eye Institute
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
David Eichenbaum, MD, is a consultant for Alimera Sciences, Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Coherus BioSciences, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, Gyroscope, IVERIC bio, Inc, KKR, Kodiak Sciences Inc, Novartis Pharmaceuticals Corporation, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, USRetina, and Vial; is on the speakers bureau for Allergan, Apellis Pharmaceuticals, Bausch & Lomb Incorporated, Bayer Corporation, D.O.R.C. Dutch Ophthalmic Research Center (International) B.V., EyePoint Pharmaceuticals, Genentech, Inc, and Novartis Pharmaceuticals Corporation; is a contracted researcher for Alkahest, Inc, Annexon Inc, AsclepiX Therapeutics, Bayer Corporation, EyePoint Pharmaceuticals, Gemini Therapeutics, Genentech, Inc, Gyroscope, Ionis Pharmaceuticals, Inc, IVERIC bio, Inc, Kodiak Sciences Inc, Mylan NV, NGM Biopharmaceuticals, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Opthea, Recens Medical, Inc, Regeneron Pharmaceuticals, Inc, Regenxbio Inc, and Unity Biotechnology; and has individual stocks or stock options in Boston Image Reading Center, Clearside Biomedical, Inc, Hemera Biosciences, Outlook Therapeutics, Inc, and USRetina.
Dilraj S. Grewal, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, Genentech, Inc, and IVERIC bio, Inc.
Daniel F. Kiernan, MD, is a consultant for Allergan, EyePoint Pharmaceuticals, and Physician Recommended Nutraceuticals; is on the speakers bureau for Allergan, EyePoint Pharmaceuticals, Mallinckrodt, Novartis Pharmaceuticals Corporation, Physician Recommended Nutraceuticals, Regeneron Pharmaceuticals, Inc, and Spark Therapeutics, Inc; and is a contracted researcher for Alimera Sciences and Gyroscope.
Aleksandra V. Rachitskaya, MD, is a consultant for Alcon, Genentech, Inc, IVERIC bio, Inc, Novartis Pharmaceuticals Corporation, and Zeiss; is on the speakers bureau for Apellis Pharmaceuticals and Genentech, Inc; and is a contracted researcher for AGTC, Apellis Pharmaceuticals, Genentech, Inc, and Novartis Pharmaceuticals Corporation.
Gennady Landa, MD, formerly served as an an advisory board member of EyePoint Pharmaceuticals within the past 2 years, but that relationship has ended.
Planners, Managers, and Writers
Carrie Allen, PharmD, BCPP, BCPS, MedEdicus Content Manager for this activity, was previously employed by CVS within the past 2 years, but that relationship has ended.
Medical Writer: Tony Realini, MD, is a consultant for Belkin Laser, New World Medical, Inc, Ocular Therapeutix, Inc, Oyster Point Pharma Inc, and Sight Sciences. He formerly served as a consultant for iStar Medical and Ivantis Inc within the past 2 years, but those relationships have ended.
Other MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from EyePoint Pharmaceuticals.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC or EyePoint Pharmaceuticals.
©2022 MedEdicus LLC. 272
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation